ATE285229T1 - Neuer filmüberzug - Google Patents

Neuer filmüberzug

Info

Publication number
ATE285229T1
ATE285229T1 AT02715942T AT02715942T ATE285229T1 AT E285229 T1 ATE285229 T1 AT E285229T1 AT 02715942 T AT02715942 T AT 02715942T AT 02715942 T AT02715942 T AT 02715942T AT E285229 T1 ATE285229 T1 AT E285229T1
Authority
AT
Austria
Prior art keywords
film coating
film
core
coating composition
pharmaceutical
Prior art date
Application number
AT02715942T
Other languages
English (en)
Inventor
Arne Hoelzer
Jan-Erik Loefroth
Staffan Schantz
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE285229T1 publication Critical patent/ATE285229T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paints Or Removers (AREA)
  • Surface Treatment Of Glass Fibres Or Filaments (AREA)
  • Laminated Bodies (AREA)
AT02715942T 2001-01-24 2002-01-22 Neuer filmüberzug ATE285229T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100200A SE0100200D0 (sv) 2001-01-24 2001-01-24 New film coating
PCT/SE2002/000103 WO2002058677A1 (en) 2001-01-24 2002-01-22 New film coating

Publications (1)

Publication Number Publication Date
ATE285229T1 true ATE285229T1 (de) 2005-01-15

Family

ID=20282714

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02715942T ATE285229T1 (de) 2001-01-24 2002-01-22 Neuer filmüberzug

Country Status (22)

Country Link
US (1) US7959947B2 (de)
EP (1) EP1355635B1 (de)
JP (1) JP4303471B2 (de)
KR (1) KR100874582B1 (de)
CN (1) CN1218692C (de)
AT (1) ATE285229T1 (de)
AU (1) AU2002225573B2 (de)
BR (1) BR0206515A (de)
CA (1) CA2433530A1 (de)
DE (2) DE20220901U1 (de)
DK (1) DK1355635T3 (de)
ES (1) ES2233804T3 (de)
HK (1) HK1063432A1 (de)
IL (2) IL156623A0 (de)
MX (1) MXPA03006419A (de)
NO (1) NO20033305D0 (de)
NZ (1) NZ526792A (de)
PT (1) PT1355635E (de)
SE (1) SE0100200D0 (de)
SI (1) SI1355635T1 (de)
WO (1) WO2002058677A1 (de)
ZA (1) ZA200305457B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
CA2435729C (en) * 2001-12-19 2005-12-13 Astrazeneca Ab New film coating
SI1476138T1 (sl) * 2002-02-21 2012-07-31 Valeant Internat Barbados Srl Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
SE0201110D0 (sv) * 2002-04-12 2002-04-12 Astrazeneca Ab New film coating
SE0202353D0 (sv) * 2002-08-01 2002-08-01 Astrazeneca Ab New film coating
AU2003282375A1 (en) * 2003-02-05 2004-08-30 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
BRPI0415557A (pt) * 2003-10-31 2006-12-26 Hexal Ag formulação contendo ingrediente ativo farmacêutico com revestimento
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
DK1799196T3 (en) 2004-10-08 2016-08-15 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP2379062A1 (de) * 2009-01-09 2011-10-26 Forward Pharma A/S Pharmazeutische zusammensetzung mit ein oder mehr fumars?ureestern
UA112975C2 (uk) 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
US20100303920A1 (en) * 2009-05-27 2010-12-02 Johan Hjartstam Aqueous Film Coating Composition / 841
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
ES2728850T3 (es) * 2012-05-02 2019-10-29 Capsugel Belgium Nv Dispersiones acuosas de acetato acetato succinato de hidroxipropilmetilcelulosa (HPMCAS)
CN105007902A (zh) 2013-02-13 2015-10-28 赢创罗姆有限公司 包含大量的两种丸粒的多颗粒药物组合物
EP3065720A1 (de) 2013-11-04 2016-09-14 Capsugel Belgium NV Verfahren und systeme zur verbesserten bioverfügbarkeit von aktiven pharmazeutischen inhaltsstoffen mit esomeprazol
CN105085778B (zh) * 2014-04-22 2018-11-16 广东华润涂料有限公司 用于缓释功能成分的涂料组合物用水性胶乳、其制备方法以及应用
CN107666913B (zh) * 2015-03-03 2021-11-26 萨尼奥纳有限责任公司 特索芬辛，β-受体阻滞剂组合制剂
US10703971B2 (en) * 2016-06-30 2020-07-07 Beckman Coulter, Inc. Chemiluminescent substrates
EP3768378A4 (de) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. Neuartiges verfahren zur verlangsamung der ventrikulären rate

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB878234A (en) 1958-12-18 1961-09-27 Roehm & Haas Gmbh Pharmaceutical coating compositions
DE1228757B (de) * 1962-06-28 1966-11-17 Haessle Ab Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3341338A (en) * 1965-05-28 1967-09-12 Union Carbide Corp Polysiloxane polish formulations
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US4330338A (en) * 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4916171A (en) * 1984-07-25 1990-04-10 Rohm And Haas Company Polymers comprising alkali-insoluble core/alkali-soluble shell and copositions thereof
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
CH666405A5 (de) * 1985-06-24 1988-07-29 Ciba Geigy Ag Feste, haltbare darreichungsformen mit elastischem filmueberzug.
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
US4975283A (en) * 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US4871546A (en) * 1987-06-29 1989-10-03 Sandoz Pharm. Corp. Gastrointestinal protective coating formulations
EP0313845A1 (de) 1987-09-29 1989-05-03 Warner-Lambert Company Stabilisierung von enterischen beschichteten Dosierungsformen
FR2655266B1 (fr) 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
US5484597A (en) * 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE4444051A1 (de) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
CA2435729C (en) * 2001-12-19 2005-12-13 Astrazeneca Ab New film coating
SE0201110D0 (sv) * 2002-04-12 2002-04-12 Astrazeneca Ab New film coating
SE0202353D0 (sv) * 2002-08-01 2002-08-01 Astrazeneca Ab New film coating

Also Published As

Publication number Publication date
PT1355635E (pt) 2005-04-29
AU2002225573B2 (en) 2006-09-07
SI1355635T1 (en) 2005-06-30
MXPA03006419A (es) 2003-10-15
DK1355635T3 (da) 2005-03-29
KR20030070122A (ko) 2003-08-27
JP4303471B2 (ja) 2009-07-29
SE0100200D0 (sv) 2001-01-24
US7959947B2 (en) 2011-06-14
ZA200305457B (en) 2004-10-15
NZ526792A (en) 2004-12-24
ES2233804T3 (es) 2005-06-16
IL156623A0 (en) 2004-01-04
KR100874582B1 (ko) 2008-12-16
CA2433530A1 (en) 2002-08-01
EP1355635B1 (de) 2004-12-22
DE60202351D1 (de) 2005-01-27
NO20033305L (no) 2003-07-22
BR0206515A (pt) 2004-02-17
IL156623A (en) 2007-12-03
WO2002058677A1 (en) 2002-08-01
NO20033305D0 (no) 2003-07-22
JP2004522741A (ja) 2004-07-29
EP1355635A1 (de) 2003-10-29
DE20220901U1 (de) 2004-06-17
CN1487828A (zh) 2004-04-07
HK1063432A1 (en) 2004-12-31
CN1218692C (zh) 2005-09-14
DE60202351T2 (de) 2005-12-01
US20040058001A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
ATE285229T1 (de) Neuer filmüberzug
WO2002072033A3 (en) Chronotherapeutic dosage forms containing glucocorticosteroid
IT1289160B1 (it) Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
CA2290531A1 (en) Pharmaceutical formulation of omeprazole
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
SE9803772D0 (sv) Pharmaceutical formulation
WO2001062737A3 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
WO2005027843A3 (en) Chronotherapeutic dosage forms
DE60210552D1 (de) Prozess zur Herstellung einer festen pharmazeutischen Zubereitung welche einen schwerlöslichen Wirkstoff enthält
FR2826343B1 (fr) Dispositif pour la pulverisation d'un produit, notamment sous forme de dose echantillon
DE60042972D1 (de) Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
ITBO970640A0 (it) Apparecchio per l'elettroemanazione di principi attivi.
MXPA03007635A (es) P-tienilbencilamidas que sirven como agonistas de receptores para angiotensina-(1-7), metodo para su produccion, su uso y preparaciones farmaceuticas que las contienen.
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
AU5812800A (en) Pharmaceutical preparation
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
HK1086819A1 (en) 2-(butyl-1-sulfonylamino)-n-(1(r)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
EP1245562A4 (de) 5-thia-"omega"-(substituiertes phenyl)-prostaglandin e alkohole, verfahren zur herstellung der alkohole und pharmzeutische zusammensetzungen, die diese als aktive inhaltsstoffe enthalten
WO2003035043A3 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
PL357466A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
DK1275383T3 (da) "Modified release" farmaceutisk komposition, der indeholder Bupropion HCI som aktivt stof
AU2002215044A1 (en) 2-(2-(4-((2r)-2-methyl-3-(10h-phenothiazin-10-yl)propyl)-1-p iperazinyl)-ethoxy)ethanol, process for the preparation thereof, pharmaceutical compositions containing said compound and therapeutic uses thereof
BRPI0414787A (pt) comprimidos revestidos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355635

Country of ref document: EP